Status:
COMPLETED
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
Lead Sponsor:
University of Bergen
Conditions:
Acute Myelogenous Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Hypothesis: Combined treatment with valproic acid and ATRA can be used to achieve disease stabilization for a subset of patients with acute myelogenous leukemia (AML), and this effect can be improved ...
Detailed Description
Patients to be included: 1. Elderly patients (\>60 years of age) or other patients unfit for conventional intensive chemotherapy with newly diagnosed acute myelogenous leukemia (AML). 2. Adult patien...
Eligibility Criteria
Inclusion
- Recently diagnosed AML in patients unfit for intensive chemotherapy
- Patients with relapsed or refractory AML
Exclusion
- No informed consent
- Intolerance to study drugs
- Serious liver disease
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00995332
Start Date
September 1 2009
End Date
June 1 2013
Last Update
June 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland University Hospital and University of Bergen
Bergen, Norway, N-5021